Literature DB >> 3314526

Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis.

H M Lazarus1, M E Hartnett, M D Reed, B F Murphy, J H Lass.   

Abstract

In a double-masked, randomized fashion, 11 patients with hematologic malignancies received 13 courses of high-dose cytarabine therapy, intravenously (3 g/m2 every 12 hours for five to six days). Each patient received topical prednisolone phosphate 1% in one eye and 2-deoxycytidine 100 microM in the other eye every six hours. Topical therapy was initiated 12 hours before the first cytarabine dose and continued for up to ten days (until four to five days after completion of cytarabine therapy). Slit-lamp biomicroscopy was performed before therapy and then weekly for one month. 2-Deoxycytidine was equally as effective as the topical corticosteroid therapy in reducing photophobia and pain, microcysts, and punctate epithelial erosions, and each treatment gave results significantly better when compared historically to placebo-treated eyes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3314526     DOI: 10.1016/s0002-9394(14)74104-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Ocular surface toxicity associated with topical interferon alpha-2b.

Authors:  Anthony J Aldave; Anne Nguyen
Journal:  Br J Ophthalmol       Date:  2007-08       Impact factor: 4.638

Review 2.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

3.  Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato; Akiko Yamane; Yoshinobu Aisa; Yusuke Kawata; Mayu Ichimura; Chiaki Tsuneyama; Tomoko Yashima; Yoko Ogawa; Kazuo Tsubota; Naoyuki Shigematsu; Takayuki Shimizu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-08-19       Impact factor: 2.490

Review 4.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

5.  Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients

Authors:  Gökçen Özcan; Ömür Özlenen Uçakhan
Journal:  Turk J Ophthalmol       Date:  2021-04-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.